Shedrx vs LifeMD: Key Clinical Differences for GLP-1 Care

Last reviewed: May 17, 2026

Last updated: May 17, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Shedrx and LifeMD are both telehealth platforms offering GLP-1 medications, yet they operate with different clinical frameworks, provider structures, and evaluation protocols. Comparing them requires understanding not just price and convenience, but also baseline health screening depth and prescribing oversight.

Patients selecting a telehealth GLP-1 provider should consider how thoroughly each platform assesses individual factors—medical history, medication interactions, metabolic profile—before starting treatment. Precision-focused telehealth relies on robust initial evaluation to identify which patients benefit most and which need additional monitoring.

How Shedrx and LifeMD Structure Provider Oversight

Shedrx primarily uses nurse practitioners and physician assistants to conduct initial assessments and prescribe GLP-1 medications. LifeMD similarly employs licensed providers but operates with variable credential levels depending on state regulations and program tier. Both platforms offer asynchronous or synchronous consultations, though response times and provider availability differ.

The distinction matters clinically: prescribing oversight varies by credential type and by whether a supervising physician reviews each patient case. Some telehealth models employ collaborative oversight; others allow independent prescribing within state scope of practice. Patients should verify whether their chosen platform includes physician review or relies solely on non-physician provider decision-making.

Baseline Health Evaluation and Risk Screening Framework

A robust GLP-1 evaluation should include medical history, current medications, kidney and liver function assessment, family history of thyroid or pancreatitis risk, and cardiovascular baseline. The depth and documentation of this screening directly affects safety and prescription appropriateness. Below is a framework of key assessment elements that should be present before GLP-1 initiation.

Assessment Element	Clinical Significance
Medical history and comorbidities	Identifies contraindications, prior drug reactions, and conditions affecting GLP-1 safety
Kidney and liver function labs	GLP-1 metabolites clear renally; liver function guides dosing and monitoring
Thyroid history and screening	GLP-1 may accelerate pre-existing thyroid disease; baseline thyroid status essential
Pancreatitis and gallbladder risk	GLP-1 associated with rare pancreatitis risk; prior episodes warrant closer monitoring
Current medication review	Identifies interactions, especially with insulin or sulfonylureas requiring dose adjustment
Cardiovascular baseline	Establishes reference for monitoring heart rate, blood pressure, and GLP-1 effects

Medication Options and Compounded vs. Branded Availability

Shedrx and LifeMD typically prescribe branded GLP-1 medications (Ozempic, Wegovy, Zepbound, Mounjaro) sourced through standard pharmaceutical channels. Both platforms may also discuss compounded options, though availability and formulary coverage vary. Compounded semaglutide and tirzepatide offer alternative pathways when branded formulations face supply constraints or when patients seek cost-adjusted dosing under provider supervision.

Compounded medications manufactured by licensed 503A pharmacies differ in formulation, stability, and regulatory pathway compared to branded products. Patients should understand that compounded options may have different pricing structures and require a provider willing to prescribe from a compounding partner. All GLP-1 options—branded or compounded—require ongoing clinical monitoring and dose adjustment based on individual response and tolerability.

Safety Monitoring, Follow-up Protocols, and Who Should Start GLP-1

Both Shedrx and LifeMD should offer structured follow-up protocols at 2–4 weeks post-initiation and ongoing check-ins to assess tolerability, side effects, and metabolic response. Ideal protocols include provider access for urgent questions, side-effect management guidance, and dose escalation oversight. Patients with complex medical histories, multiple medications, or prior adverse reactions benefit from platforms offering more frequent provider contact and detailed clinical notes.

GLP-1 therapy is not appropriate for all patients. Absolute contraindications include personal or family history of medullary thyroid cancer, Multiple Endocrine Neoplasia type 2, and pregnancy. Relative cautions include prior pancreatitis, severe kidney disease, and certain cardiovascular conditions. Before enrolling in any telehealth platform, patients should have a clear provider evaluation confirming safety and appropriateness for their individual clinical context.

How PlexusDx Supports a More Personalized Approach

PlexusDx offers compounded GLP-1 medications (semaglutide, tirzepatide, and GLP-Squared formulations) paired with optional Precision Peptide Genetic Testing. Genetic biomarkers in GLP-1 and GLP-1R pathways may help provide context about individual predispositions in peptide sensitivity and metabolic response. This information should be interpreted by a qualified provider to support more informed discussion about dosing, formulation choice, and monitoring expectations.

The Precision Peptide Genetic Test evaluates variants in GLP1R, GIPR, FTO, and MC4R genes—markers associated with peptide pathway function and metabolic predisposition. The test reveals genetic context that may complement clinical evaluation, though genetic predisposition does not predict exact medication response or guarantee outcomes. Many patients benefit from understanding their genetic framework alongside standard clinical assessment.

When comparing telehealth GLP-1 providers, consider whether a platform offers biomarker or genetic context as part of personalized care. PlexusDx integrates genetic testing as an optional add-on to support deeper provider conversation about why a specific formulation, dose, or compound might align with individual biology. This approach complements thorough clinical evaluation and may help patients and providers make more informed, precision-focused decisions.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the main clinical difference between how Shedrx and LifeMD evaluate patients before prescribing GLP-1?

Both platforms require baseline health screening, but depth and documentation vary by provider credential and platform protocol. Verify whether your chosen platform includes physician oversight review, lab order capacity, and how thoroughly they assess kidney function, thyroid status, and pancreatitis risk before prescribing.

Can I use compounded GLP-1 medications through Shedrx or LifeMD?

Some telehealth platforms offer compounded options, though branded medications remain primary offerings. Compounded semaglutide and tirzepatide require a provider willing to prescribe from a licensed 503A compounding pharmacy. Availability depends on platform partnerships and state regulations.

How does PlexusDx differ from Shedrx and LifeMD in approach?

PlexusDx specializes in compounded GLP-1 medications from licensed 503A pharmacies and offers optional Precision Peptide Genetic Testing to provide biomarker context. This genetic framework may support more personalized provider conversations alongside standard clinical evaluation and dose optimization.

What safety factors should I confirm before starting GLP-1 with any telehealth provider?

Ensure your provider reviews kidney and liver function labs, thyroid history, pancreatitis risk, current medications, and cardiovascular baseline. Confirm they have protocols for follow-up monitoring at 2–4 weeks and ongoing access for side-effect management. Avoid any provider unwilling to document these assessments thoroughly.

Does genetic testing predict how well I will respond to GLP-1 medication?

Genetic testing reveals predispositions in peptide pathways but does not predict exact medication response. Variants in GLP1R, GIPR, FTO, and MC4R genes may provide context, but clinical response depends on multiple factors including diet, lifestyle, dosing, and individual metabolism. Testing should support provider conversation, not replace cli...

Shedrx vs LifeMD: Clinical Considerations Before Choosing a Telehealth GLP-1 Provider